Great things are happening to the stocks in this article.
They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table?
Intel continued its winning run amid news of new strategic investment, while Nvidia saw activity as traders geared up for its quarterly results due next week.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with Zoetis (NYSE:ZTS).
Markets watch for the Trump–Putin meeting tomorrow that could impact Russia–Ukraine peace talks. Analysts see 24,600 as a make-or-break level for Nifty ahead of weekly expiry volatility.
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Wednesday and uncover the stocks that are leading the way in terms of trading volume and market attention.
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy.
Bristol-Myers Squibb’s second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year. Despite these beats, the market responded negatively, reflecting concerns raised by management about continued macro and competitive pressures. CEO Chris Boerner pointed to strong demand across the company’s growth portfolio, especially in oncology and hematology, while also acknowledging regulatory wins and cost optimization initiatives. The quarter was further shaped by the launch of new therapies and an increased focus on reshaping the business for long-term growth.
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $14.65 billion. The company expects the full year’s revenue to be around $62.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.78 per share was 35.9% above analysts’ consensus estimates.
Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for both revenue and non-GAAP earnings. Management attributed this performance to a robust showing across its commercial portfolio, especially in oncology, vaccines, and rare disease products. CEO Albert Bourla highlighted that disciplined cost control and productivity enhancements—including expanded use of automation and AI—contributed to improved operating margins. The company also benefited from higher-than-anticipated demand for several newly launched products and continued international momentum, particularly for its Vyndaqel family and key oncology brands.
Pfizer, Inc. stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just over 8x this year's estimates and 7.8x next year.
